Poly(I:C) Formulation pH Adjustment for Aggregation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations of Poly(I:C) molecules, such as BO-11X compositions, face challenges in maintaining biophysical and biological efficacy during administration, particularly when administered in large volumes or at low flow rates, leading to adverse reactions and particle aggregation.
Innovation Solution
The development of aqueous formulations, like BO-11XSQ, which involve mixing Poly(I:C) molecules with a deacidifying solution to adjust the pH to a range of 4.5 to 8.5, using buffers like sodium bicarbonate, to enhance stability and minimize particle loss and aggregation, making them suitable for parenteral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Poly(I:C) formulations are administered in large volumes or at low flow rates, then the therapeutic coverage and treatment efficacy are improved, but particle aggregation and adverse reactions increase
Solution Approach 1:
The patent applies parameter changes by adjusting the pH of the formulation to a physiological range (pH 4.5-8.5, preferably pH 6.0-7.5) using deacidifying solutions. This pH adjustment fundamentally changes the chemical environment to prevent particle aggregation during large-volume or low-flow-rate administrations, thereby resolving the contradiction between administration volume and particle stability.
2Quantity of substance
If Poly(I:C) formulations are administered in large volumes, then the therapeutic coverage is improved, but adverse local reactions at the injection site increase
Solution Approach 1:
The patent changes the pH parameter of the formulation to match physiological conditions (pH 4.5-8.5). This parameter adjustment reduces the chemical irritation and adverse local reactions that occur during large-volume administrations, allowing for improved therapeutic coverage without compromising patient comfort or safety.
3Reliability
If the pH of BO-11X formulations is adjusted to physiological range, then clinical acceptability and stability are improved, but particle loss and aggregation may occur
Solution Approach 1:
The patent introduces deacidifying solutions (intermediary substances) such as sodium bicarbonate, phosphate buffers, or citrate buffers to mediate the pH adjustment process. These intermediary agents facilitate the transition to physiological pH while minimizing direct interactions that could cause particle loss or aggregation, thereby maintaining formulation stability.
Solution Approach 2:
The patent applies preliminary action by pre-adjusting the pH of the formulation before administration. This advance pH adjustment ensures that the formulation is already in the optimal physiological pH range (pH 4.5-8.5) before entering the body, preventing particle aggregation and loss during storage and administration without requiring in-situ adjustments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The BO-11XSQ formulations maintain the therapeutic efficacy of Poly(I:C) molecules with minimal loss and aggregation, reducing adverse reactions and improving clinical acceptability, especially during large-volume or low-flow-rate administrations.
Implementation Method 1
mixing a composition comprising particles that are formed by polymers and Poly(I:C) molecules using a deacidifying solution that is selected among established clinically acceptable buffers useful for drug administration
Data Source
AI summary
An aqueous formulation, comprising particles formed by a combination of polyinosinic-polycytidylic acid [Poly(I:C)] molecules and polyethyleneimine, wherein the formulation comprises a pH of between pH 5.0 and pH 7.5. Said composition for use in therapy, wherein the therapy is stimulating an immune response, treating or preventing cancer, or a vaccine therapy.